Overall survival. ASC, active symptom control; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; HR, hazard ratio; CI, confidence interval. *Numbers are cumulative. Reprinted from the article of Lamarca et al. (Lancet Oncol 2021;22:690-701) [5].|@|~(^,^)~|@|Grade 3–5 adverse events and chemotherapy-related toxicity. Grade 3–5 adverse events reported at least in 1% of patients in the ASC plus FOLFOX group that were considered to be chemotherapy related are summarised, alongside the incidence in each study group regardless of causality. Percentages are calculated in the intention-to-treat population. ASC, active symptom control; FOLFOX, folinic acid, fluorouracil, and oxaliplatin. *Includes liver infection, increased bilirubin or alkaline phosphatase, and hepatitis. Reprinted from the article of Lamarca et al. (Lancet Oncol 2021;22:690-701) [5].

© JDCR